Phytochemicals as Lead Compounds for New Drug Discovery
- 1st Edition - September 7, 2019
- Editors: Chukwuebuka Egbuna, Shashank Kumar, Jonathan C. Ifemeje, Shahira M. Ezzat, Saravanan Kaliyaperumal
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 7 8 9 0 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 7 8 9 1 - 1
Phytochemicals as Lead Compounds for New Drug Discovery presents complete coverage of the recent advances in the discovery of phytochemicals from medicinal plants as models to the… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePhytochemicals as Lead Compounds for New Drug Discovery presents complete coverage of the recent advances in the discovery of phytochemicals from medicinal plants as models to the development of new drugs and chemical entities. Functional bioactive compounds of plant origin have been an invaluable source for many human therapeutic drugs and have played a major role in the treatment of diseases around the world. These compounds possess enormous structural and chemical diversity and have led to many important discoveries. This book presents fundament concepts and factors affecting the choice for plant-based products, as well as recent advances in computer-aided drug discovery and FDA drug candidacy acceptance criteria. It also details the various bioactive lead compounds and molecular targets for a range of life-threatening diseases including cancer, diabetes, and neurodegenerative diseases.
Written by a global team of experts, Phytochemicals as Lead Compounds for New Drug Discovery is an ideal resource for drug developers, phytochemists, plant biochemists, food and medicinal chemists, nutritionists and toxicologists, chemical ecologists, taxonomists, analytical chemists, and other researchers in those fields. It will also be very valuable to professors, students, and researchers in this domain.
- Presents fundamental concepts and factors affecting choice for plant-based products
- Details the FDA drug candidacy acceptance criteria, including bottlenecks and way forward
- Highlights recent advances in computational-based drug discovery
- Focuses on the discovery of new drugs and potential druggable targets for the treatment of chronic diseases of world importance
Researchers working in drug development, phytochemists, plant biochemists, food and medicinal chemists, nutritionists, toxicologists, chemical ecologists, taxonomists, and analytical chemists
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Biography
- Part I. Plants as natural sources of drugs
- Chapter 1. Plant secondary metabolites as lead compounds for the production of potent drugs
- 1.1. Medicinal plants and phytochemicals
- 1.2. Conclusion
- Chapter 2. Factors affecting the choice for plant-based products in drug discoveries
- 2.1. Introduction
- 2.2. Conclusion
- Chapter 3. Advances in computer-aided drug discovery
- 3.1. Introduction
- Chapter 4. FDA drug candidacy acceptance criteria and steps: problems and way forward
- 4.1. Introduction
- Part II. Biofunctional leads for drug development
- Chapter 5. Bioactive lead compounds and molecular targets for the treatment of heart diseases
- 5.1. Introduction
- 5.2. Natural products targeting autophagy and cardiovascular disorders
- 5.3. Natural products targeting endoplasmic reticulum (ER) and cardiovascular diseases
- 5.4. Atherosclerosis and chronic inflammation
- 5.5. Selected classes of natural products used in the prevention of hypertension and ischaemic heart diseases by various mechanisms
- 5.6. Natural products in preclinical/clinical studies
- Chapter 6. Natural bioactive lead compounds effective against haematological malignancies
- 6.1. Introduction
- Chapter 7. Adjunct therapeutic potential of phytochemicals against cancer
- 7.1. Introduction
- Chapter 8. Antidiabetic lead compounds and targets for drug development
- 8.1. Introduction
- 8.2. Molecular targets of antidiabetic drugs
- 8.3. Phytochemicals in diabetes management
- 8.4. Classes of antidiabetic drugs currently used
- 8.5. Antidiabetic drugs on clinical trial
- 8.6. Future directions
- 8.7. Conclusion
- Chapter 9. Antiobesity functional leads and targets for drug development
- 9.1. Introduction
- Chapter 10. Phytochemicals as therapeutic interventions in neurodegenerative diseases
- 10.1. Introduction
- Chapter 11. Organosulfur phytochemicals against metabolic and neurodegenerative diseases: benefits and risks
- 11.1. Introduction to phytochemicals: chemistry and classification
- Chapter 12. Lead compounds with the potentials for the treatment of chronic liver diseases
- 12.1. Introduction
- Chapter 13. Bioactive lead compounds effective against skin diseases
- 13.1. Introduction
- Chapter 14. Phytochemicals as emerging therapeutic agents for alopecia treatment
- 14.1. Introduction
- Chapter 15. Antiviral phytocompounds for drug development: a data mining studies
- 15.1. Introduction
- Chapter 16. Shikimic acid as intermediary model for the production of drugs effective against influenza virus
- 16.1. Introduction
- 16.2. Influenza and its various forms
- Chapter 17. Antimicrobial lead compounds from marine plants
- 17.1. Introduction
- Chapter 18. Antibacterial lead compounds and their targets for drug development
- 18.1. Introduction
- Chapter 19. Awareness and current therapeutic strategies of malaria
- 19.1. Introduction
- Chapter 20. Bioactive lead compounds and targets for the development of antimalarial drugs
- 20.1. Introduction
- 20.2. Conclusion
- Chapter 21. Bioactive lead compounds and molecular targets for the development of antiinflammatory drugs
- 21.1. Introduction
- Chapter 22. Functional lead compounds and targets for the development of drugs for the treatment of male infertility
- 22.1. Introduction
- Chapter 23. Prenylated flavonoids as a promising drug discovery candidate: a pharmacological update
- 23.1. Introduction
- Index
- No. of pages: 378
- Language: English
- Edition: 1
- Published: September 7, 2019
- Imprint: Elsevier
- Paperback ISBN: 9780128178904
- eBook ISBN: 9780128178911
CE
Chukwuebuka Egbuna
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
SK
Shashank Kumar
JI
Jonathan C. Ifemeje
SE
Shahira M. Ezzat
SK